Description:Vatalanib dihydrochloride is a small molecule that functions primarily as a tyrosine kinase inhibitor, targeting various receptor tyrosine kinases involved in angiogenesis and tumor growth. It is particularly noted for its potential in cancer therapy, as it inhibits pathways that promote vascular endothelial growth factor (VEGF) signaling, thereby disrupting the blood supply to tumors. The compound is characterized by its dihydrochloride salt form, which enhances its solubility and bioavailability. Vatalanib has been studied in clinical trials for various malignancies, including solid tumors, and exhibits a favorable pharmacokinetic profile. Its mechanism of action involves the selective inhibition of multiple kinases, which can lead to reduced tumor proliferation and metastasis. As with many pharmaceutical compounds, the safety and efficacy profile of Vatalanib dihydrochloride is subject to ongoing research, and its use is guided by clinical findings and regulatory approvals. Proper handling and storage conditions are essential to maintain its stability and effectiveness in therapeutic applications.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.